ARBUTUS BIOPHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.68 USD | -0.37% |
|
-1.47% | +7.20% |
| 05-02 | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M | MT |
| 05-02 | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M | MT |
Chart calendar Arbutus Biopharma Corporation
22275b13afca79caa7eac9.9SvDACa7OMFcdhEXT-zf1OKgRy2qvgC3DxNS8RgWmYE.s3u6WHnafLQfEndVJqHsjLL2d07O2UzheCcNwH1F7dHHG5tLX4N3kx0TZg~f2a5fdfb3b492ea46168f0034c48e8bf
Upcoming events on Arbutus Biopharma Corporation
Past events on Arbutus Biopharma Corporation
| 02/05/2024 13:45 | Q1 2024 Earnings Call |
| 02/05/2024 12:30 | Q1 2024 Earnings Release |
| 12/03/2024 | Jefferies Biotech on the Bay Summit |
| 12/03/2024 18:05 | Barclays Global Healthcare Conference |
| 29/02/2024 13:45 | Q4 2023 Earnings Call |
| 29/02/2024 12:30 | Q4 2023 Earnings Release |
| 15/11/2023 11:30 | Jefferies London Healthcare Conference |
| 13/11/2023 18:00 | American Association for the Study of Liver Diseases Conference - Abstract Number: 46646 |
| 12/11/2023 13:30 | American Association for the Study of Liver Diseases Conference - Abstract Number: 40653 |
| 10/11/2023 17:00 | American Association for the Study of Liver Diseases Conference - Abstract Number: 45559 |
| 09/11/2023 | American Association for the Study of Liver Diseases Conference - Man-Fung Yuen |
| 07/11/2023 13:45 | Q3 2023 Earnings Call |
| 07/11/2023 12:30 | Q3 2023 Earnings Release |
| 25/10/2023 21:30 | H.C. Wainwright NASH Investor Conference |
| 13/09/2023 12:55 | Bairds Global Healthcare Conference |
| 12/09/2023 20:30 | H.C. Wainwright Global Investment Conference |
| 03/08/2023 13:45 | Q2 2023 Earnings Call |
| 03/08/2023 12:30 | Q2 2023 Earnings Release |
| 23/06/2023 | European Association for the Study of the Liver Congress - Abstract No:1281 |
| 20/06/2023 | European Association for the Study of the Liver Congress - Abstract No:4112 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CAD | Released Forecast Spread | 8,06 14,9 -45.79% | 8,72 8,40 3.8% | 13,9 13,5 3.11% | 53,1 52,5 1.25% | 24,6 28,3 -13.05% | 12,0 |
|
EBITDA Million CAD | Released Forecast Spread | -93,2 -79,8 -16.73% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million CAD | Released Forecast Spread | -193 -165 -17.19% | -72,9 -71,8 -1.56% | -93,1 -89,7 -3.77% | -89,1 -85,3 -4.45% | -106 -108 2.15% | -130 |
|
Earnings before Tax (EBT) Million CAD | Released Forecast Spread | -223 -182 -22.86% | -80,4 -81,9 1.85% | -96,6 -93,3 -3.55% | -88,5 -85,5 -3.55% | -98,9 -101 2.23% | -122 |
|
Net income Million CAD | Released Forecast Spread | -221 -207 -6.92% | -95,7 -87,9 -8.8% | -112 -105 -6.16% | -94,6 -90,7 -4.27% | -98,9 -99,8 0.86% | -122 |
|
EPS CAD | Released Forecast Spread | -3,88 -3,58 -8.24% | -1,26 -1,26 -0.44% | -1,05 -1,09 3.58% | -0,63 -0,61 -2.9% | -0,60 -0,61 1.69% | -0,60 |
| Announcement Date | 05/03/20 | 04/03/21 | 03/03/22 | 02/03/23 | 29/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CAD | Released Forecast Spread | 4,06 3,64 11.49% | 16,1 5,54 191.4% | 18,3 8,71 110.11% | 8,01 12,4 -35.38% | 8,50 8,31 2.28% | 9,11 8,23 10.61% | 6,20 8,29 -25.21% | 6,37 6,41 -0.54% | 2,91 6,51 -55.28% | 2,11 3,68 -42.75% | 3,85 | 3,75 | 3,51 | 2,91 |
|
EBIT Million CAD | Released Forecast Spread | -26,3 -23,3 -13.05% | -14,1 -22,8 38.3% | -18,1 -24,4 25.74% | -24,0 -25,1 4.6% | -30,7 -27,6 -11.13% | -23,7 -30,4 21.91% | -24,5 -26,2 6.53% | -29,5 -28,0 -5.14% | -28,2 -30,1 6.48% | -26,6 -27,7 3.95% | -30,9 | -33,3 | -36,6 | -45,3 |
|
Earnings before Tax (EBT) Million CAD | Released Forecast Spread | -27,0 -24,0 -12.29% | -14,5 -22,2 34.66% | -18,2 -24,9 26.72% | -23,6 -25,4 6.82% | -29,9 -27,5 -8.4% | -22,3 -29,9 25.54% | -22,8 -25,3 9.92% | -27,5 -26,9 -2.13% | -26,2 -28,2 6.88% | -24,6 -25,8 4.7% | -28,9 | -31,4 | -34,7 | -43,3 |
|
Net income Million CAD | Released Forecast Spread | -27,7 -26,6 -4.42% | -20,2 -23,5 13.99% | -18,2 -24,9 26.72% | -23,6 -25,4 6.82% | -29,9 -27,5 -8.4% | -22,3 -29,9 25.54% | -22,8 -25,2 9.58% | -27,5 -26,9 -2.13% | -26,2 -28,2 6.88% | -24,6 -25,8 4.7% | -28,9 | -31,4 | -34,7 | -43,3 |
|
EPS CAD | Released Forecast Spread | -0,19 -0,24 20.97% | -0,14 -0,20 30.24% | -0,13 -0,16 20.74% | -0,16 -0,17 4.34% | -0,19 -0,18 -5.65% | -0,14 -0,19 26.54% | -0,13 -0,15 11.23% | -0,16 -0,15 -6.56% | -0,16 -0,16 -1.19% | -0,14 -0,15 7.81% | -0,15 | -0,16 | -0,17 | -0,20 |
| Announcement Date | 03/03/22 | 05/05/22 | 04/08/22 | 09/11/22 | 02/03/23 | 04/05/23 | 03/08/23 | 07/11/23 | 29/02/24 | 02/05/24 | - | - | - | - |
More events
Past sector events for Arbutus Biopharma Corporation
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ABUS Stock
- Calendar Arbutus Biopharma Corporation
